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Abstract
The spread of healthcare-associated infections has become a matter of global concern. These infections, which 
were once solely limited to hospital settings, have emerged in the community. Reduced infection control 
practices strengthen this rapid spread of infections, which has led to the increase in the occurrence of multi-
drug resistant organisms. The state of infection control in the United Kingdom is of extreme importance because 
of several reported cases of infections caused by these organisms. In addition to antimicrobial usage in human 
medicine, antimicrobial agents used in agriculture must be considered as major factors in the prevalence 
of resistant organisms and the implications to the UK. However, this increased occurrence of antimicrobial 
resistant bacteria and their resulting infections could be reduced with the application of effective policies for 
antibiotic use in agricultural environments, stringent decontamination and sterilisation techniques and better 
regulations that encourage the search for, and development of, new and novel drugs.
Keywords: Infection control, healthcare associated infections, antimicrobial drug resistance, prophylaxis, 
health policy.
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Introduction
With a prevalence of 6.4%,1 the spread of healthcare-
associated infections (HCAIs) and their subsequent 
control has become an important issue in hospitals.2 
Historically, the hospital setting was subjected to daily 
rigorous sanitisation by dedicated cleaning staff, and 
all medical students and staff had to observe a stringent 
hygiene regimen.3 Over time, there was a decrease in 
following these strict rules of hospital hygiene resulting 
in an increase in HCAIs. As a result, infection control 
practices, although not the primary cause of disease 
transmission, suffered great setbacks leading to the 
unintended spread of infectious diseases.3
Reduction in global infection control practices has 
led indirectly to the development of antimicrobial 
resistance (AMR), which is the evolution of pathogenic 
microorganisms to become resistant to anti-infective 
agents. Occurrence of these resistant microorganisms 
has increased worldwide,4 spreading to the UK and 
increasing the risks of both patients and healthcare 
workers acquiring these infections in a healthcare 
setting as reported by the National Institute for Health 
and Care Excellence (NICE).5 These infections, which 
were once mainly hospital-acquired, are now seen in 
the community and the issue of increasing resistance, 
as reported by WHO,6 to antimicrobials has also 
become an issue beyond infection control in the 
hospital environment.
This paper focuses on the current state of infection 
control in the UK in terms of the major issues 
regarding anti microbial resistance. Consideration of 
antimicrobial usage in agriculture and human medicine 
will be reviewed, as well as their consequences 
relating to the major causes of AMR, the prevalence of 
global threat from this resistance and the implications 
to the UK. The need to develop new antibiotics as a 
consequence of this issue will be considered.
Methods
The methodology used for data collection was an 
internet search using keywords and phrases related 
to infection control in the UK and antibiotic use on 
UK farms and in UK human medicine. Other phrases 
used in the search were those involving causes and 
occurrences of AMR including the importance of 
new antimicrobial agents. The internet search engines 
used included ScienceDirect, Google Scholar, the 
Antimicrobial Resistance and Healthcare-associated 
Infections (AMRHAI) reference unit, the Department 
of Public Health (UK), Public Health England and the 
World Health Organisation (WHO).
Antibiotic use on UK farms
In a 2014 Review on Antimicrobial Resistance that was 
announced by the UK Prime Minister, several measures 
were identified to deal with the growing problem of 
AMR. One of these measures was a global commitment 
to monitor the use of antibiotic drugs by humans, in 
agriculture and in the environment.7 
Although overlooked because of the restrictions placed 
on the class of antibiotics used, antimicrobial agents in 
livestock farming do contribute to AMR.8 These drugs 
are used for various reasons such as for medicinal 
purposes, whether by mass medication (metaphylaxis) 
or preventative medication (prophylaxis), and to 
promote growth of the animals. Although the use of 
antibiotics as growth aids have been banned in Europe, 
they are still being used as prophylactics.9 
In the United Kingdom, De Briyne et al.10 reported that 
penicillins and tetracylines were the most commonly 
used antibiotics in cattle (32% and 10% respectively) 
and horses (24% and 11% respectively) to treat 
disorders such as mastitis and respiratory infections. In 
another study involving 88 UK farms, heifer calves with 
respiratory diseases, e.g., pneumonia, were treated with 
antibiotics (11.3% ±15.8%).11 Despite the availability 
of guidelines on antibiotic use in agriculture, 50% of 
farmers appear to be unfamiliar with these guidelines 
leading to possible inefficient farming practices.12 
Commercially available antimicrobial agents, such as 
ivermectin, are also used on goat farms in the UK to 
treat ectoparasites such as lice and mange.13 Extensive 
use of this macrocyclic lactone and other unnamed 
antibiotics by many goat farmers may have been 
ineffectively regulated and could have contributed 
to the increase in antibiotic resistance of infectious 
ectoparasites.13 
A survey of UK broiler farms conducted by Hughes et 
al.14 showed that 32% of poultry farmers used prescribed 
antibiotics such as amoxicillin for metaphylactic 
Int J Infect Control 2017, v13:i2 doi: 10.3396/IJIC.v13i2.011.17 Page 3 of 7
not for citation purposes
Infection control in the UK Henry et al.
purposes. On some participating farms, other antibiotics 
such as trimethoprim/sulfadiazine (16.8%) and tylosin 
tartrate (11.7%) were used as prophylactics.14 Results 
of the 2008 study indicated that antibiotics were 
mainly used to prevent diseases in broilers rather than 
to treat them. Antibiotic management on broiler farms 
needs further investigation since antibiotic misuse is a 
potential factor in AMR.
United Kingdom pig farmers,  like some European pig 
farmers,15 seemed to focus more on their economic 
issues rather than infections in their animals16 leading 
to overuse of antibiotics. As a consequence, it has 
been shown that there is a clear connection between 
the poor regulation of antibiotic use in UK farms and 
AMR in humans.8
Antibiotic use in UK human medicine 
It is without doubt that antimicrobial agents have been 
effective against many human infectious diseases. The 
incidence of infectious diseases in the UK has not 
notably increased but the total usage of these agents 
have reportedly increased by 4.1% across the NHS 
Trusts in a five-year period (2008-2012).17 While there 
has been a reduction in the use of fluoroquinolones, 
such as ciprofloxacin (-23.8%), within the same 
period, the 2014 study showed that there was an 
increase in the use of other drugs such as meropenem 
of the carbapenem class (94.8%), and penicillins such 
as piperacillin/tazobactam (142.3%). While the report 
provides expected and observed data on point-of-
care antimicrobial usage, it does not show progressive 
usage, which is crucial in antimicrobial management. 
Consequential spread of infectious diarrhoea caused 
by Clostridium difficile is reported to be a major 
concern in hospitals. In a 2015 study,18 the mean 
number of patients suspected to be infected with these 
organisms was estimated to be 149.6 ± 173.6 in small 
hospitals, 75.0 ± 27.8 in medium hospitals and 43.78 
± 37.7 in large hospitals. In order to treat patients 
with diarrhoea that resulted from Clostridum difficile 
infection, metronidazole and fidaxomicin were the 
primary antimicrobial agents used while vancomycin 
was the secondary drug of choice.18 One concern that 
emerged from the study was that with the increasing 
incidence there was the possible spread of infections 
due to poor infection control practices. Without 
adequate infection control, the risk of the emergence of 
antimicrobial resistant Clostridium difficile increases. 
Since more first-line and second-line antibiotics are 
being used to treat infectious diarrhoea and a number 
of patients (mean = 10 ± 0.0) are re-admitted after an 
uncompleted course of treatment of the same drugs, 
there is the concern that AMR in Clostridium difficile 
could develop.
The concern of the spread of HCAIs was also noted 
in a 2009 study by Burnett et al.19 Findings from the 
report that focused on patients with and without 
Staphylococcus aureus septicaemia identified critical 
issues of infection control that needed attention, 
such as communication, patient confidence in the 
NHS, and health and safety practices. Antibiotics are 
understandably used against HCAIs but there is the need 
to monitor the possible spread of resistant organisms 
with increased use in a closed environment found in 
healthcare settings. Another important concern is the 
use of antibiotics by persons outside of the hospital 
environment. Antimicrobial agents are also prescribed 
by general practitioners in the community. A review 
of databases such as the Clinical Practice Research 
Datalink (CPRD) by Shallcross and Davies20 indicates 
that 80-90% of antibiotic prescriptions are given in 
primary care facilities. However, these programmes 
do not record actual use of antibiotics by patients. 
The possibility for the spread of resistant organisms 
between hospitals and community environments in 
conditions promoting the maintenance of resistance 
can be inferred.
The prevalence of antimicrobial resistance
Antimicrobial resistance is the development of reduced 
sensitivity to antimicrobial agents in microorganisms. 
Major antimicrobial resistant organisms as listed by 
Tang et al.21 include meticillin-resistant Staphylococcus 
aureus (MRSA), vancomycin-resistant enterococci 
(VRE), extended spectrum β-lactamase-producing 
(ESBL) Enterobacteriaceae, carbapenemase-producing 
Enterobacteriaceae (CPE) and carbapenem-resistant 
Acinetobacter baumannii (CRA). The main mechanisms 
of resistance in such organisms usually involve either 
the transmission of resistant genetic material from one 
bacterial cell to another or mutation/s in new genes.
Antimicrobial resistance has become a global 
epidemic resulting in the generation of AMR policies 
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in many regions, including Europe. The European 
Centre for Disease Prevention and Control (ECDC) has 
acknowledged the threat of AMR and has identified the 
major causes of the rapid spread of AMR across Europe 
with a particular source being the use of antibiotics in 
agriculture.22 A report from the B-Debate meeting with 
public health authorities across Europe stated that the 
unchecked use of antibiotics in farming practices led to 
selective pressure for resistant organisms, which could 
spread to humans.22 These resistant organisms are 
spread through human consumption of inadequately 
prepared meat products23 and dairy milk,24 and human 
contact with animal waste.25,26 Snow et al.25 determined 
that 17 of 65 sampled dairy farms received animals 
with various strains of CTX-M E. coli, which is an 
ESBL-producing microorganism. Findings of the study 
outlined insufficient infection control practices, such 
as slurry containment, open herding and inadequate 
cleaning of feeding equipment used for calves.25
Mismanaged antimicrobial chemotherapy in relation 
to ineffective infection control strategies is also a 
source of the development of AMR in bacteria as 
well as the spread of AMR bacteria. The prevalence 
of CTX-M Klebsiella pneumoniae,27 Salmonella typhi 
and Salmonella paratyphi,28 and MRSA29 has been 
documented in UK hospitals. Each study has identified 
poor infection control measures as a contributing factor 
to the spread of antimicrobial resistant microorganisms. 
While studies have found isolates of non-resistant 
Pseudomonas aeruginosa from water systems in UK 
hospital wards30 as well as isolates of non-resistant 
Staphylococcus spp from various clinical instruments,31 
the risk of AMR evolution still exists. High standards 
in infection control are crucial, especially when staff 
are charged with the care of critically ill patients who 
are most susceptible to infections from antimicrobial 
resistant organisms.32
In the community setting, unchecked prescribing 
of antimicrobial agents has been identified as a 
contributing factor to the spread of antimicrobial 
resistant bacteria.33 Due to misuse and abuse of 
antibiotics, the ECDC has recommended that antibiotic 
usage should be recorded as defined daily doses (DDD) 
over time.22 Supplementary data such as the number of 
packages used per day and details about the package 
content enhances knowledge regarding the antibiotic 
consumption.22 Support for this recommendation was 
evidenced by a European study which showed that the 
average DDD per package increased between 0.04 and 
0.31 per year.34 This marked increase in antibiotic use 
is an indication of the potential risk of antimicrobial 
resistant bacteria transmission.35
Another aspect of inadequate infection control 
is the disposal of waste containing antibiotics. 
Samples of waste water and surface water from the 
UK environment were shown to contain multiple 
antibiotics such as amoxicillin, oxytetracycline and 
trimethoprim.36 Emerging contaminants (EC) found 
in water sources at sites in Oxford along the Thames 
river and Boxford along the River Lambourn included 
pharmaceuticals.37 ECs were also found in the Chalk 
aquifer, which provides potable water to parts of the 
UK.38 The presence of antibiotics in water sources is an 
important factor in AMR since these compounds tend 
to be water-soluble and remain in the environment.39,40 
Improper waste disposal from farms and communities 
could contribute to the presence of antibiotics in UK 
water sources.41 The constant exposure of non-resistant 
bacteria to antibiotics in water sources may encourage 
the evolution of antimicrobial resistant bacteria. 
Another important consideration is the exposure of 
humans to water sources that are contaminated with 
antimicrobial resistant bacteria. A recent study showed 
that samples taken from coastal waters of England and 
Wales had a prevalence of 1.2% of 3rd generation 
cephalosporin-resistant E. coli.42 This value may be low 
since only one strain of resistant E. coli was investigated. 
Persons taking part in recreational activities in these 
areas, such as water sports, swimming and diving, 
had an increased risk of infection from  antimicrobial 
resistant bacteria due to ingestion of contaminated 
water.
Antimicrobial resistance to colistin
Colistin, also known as polymixin E, has been 
considered as a critical agent against some common 
multidrug-resistant Gram-negative aerobic bacilli, 
including CPEs. The mechanism of action of colistin 
is to damage the integrity of the outer envelope 
of Gram-negative bacilli by causing instability of 
membrane-bound lipopolysaccharides.43 This damage 
allows cellular contents to escape, which results in 
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apoptosis. Because of its toxic effects on the human 
kidney, colistin use in antimicrobial therapy was 
halted.44 However, the rapid emergence of CPEs had 
prompted the return of the usage of this drug. Overuse 
of colistin has now resulted in infections caused by 
colistin-resistant CPEs. Initially, resistance was thought 
to result from chromosomal mutations. Recent reports 
on colistin resistance in Europe, including a study 
published by the ECDC,45 revealed that resistance can 
now be mediated by the transfer of plasmids containing 
the colistin-resistant gene known as MCR-1.46–50
Infection control strategies to curb the spread  
of antimicrobial resistant bacteria
Effective infection control strategies are important in 
reducing the spread of antimicrobial resistant bacteria. 
One strategy is the implementation of policies and 
guidelines. The Department of Health has issued a 
5-year plan that involves policies to lessen the impact 
of AMR on both humans and animals. The paper 
identifies seven important actions needed to achieve 
this goal, which includes the revision of infection 
control practices in agriculture and human settings.51 
Adherence to proper and effective animal husbandry 
was recommended as a way of protecting animals 
from infectious antimicrobial resistant bacteria.9,51 
In terms of antimicrobial therapy, farmers and 
agricultural authorities should maintain accurate 
information regarding health and safety practices 
and antibiotic use.9 Other recommendations include 
a total ban of antibiotic use in prophylaxis, a ban on 
unregulated antibiotics in animals and discontinuation 
of cephalosporins and fluoroquinolones in animal 
antimicrobial chemotherapy.8
The 2013 edition of the NICE clinical guidelines 
has defined clear rules that govern infection 
control practices in both hospital and non-hospital 
environments. These include proper training of all staff, 
availability of items needed to carry out their duties 
(gloves, antiseptic agents, etc.), effective sterilisation 
and disinfection techniques and proper waste disposal 
management.52 These measures should be at the 
forefront of infection control since there has been 
an increase in public interest in CPEs in the UK.53 
Decontamination, disinfection and sterilisation have 
been identified as excellent methods of the elimination 
and extermination of infectious agents.54 Another 
method of reducing the spread of infectious organisms 
is the proper use of gloves.55
A key action of the UK five-year plan is to encourage 
research and development in new antibiotic drug 
therapies.51 Due to the overuse of antibiotics in 
humans and animals, which was first reported by 
the Swann Committee (1969) and the increase of the 
“major public health threat” of AMR as highlighted in 
House of Lords’ report (1998), there is an immediate 
need for new antibiotic drugs.56 The progress of 
novel drug discovery is limited by factors such as 
financial gain and strict regulations regarding drug 
trials and manufacture.57 Authorities have altered such 
regulations, which has revitalised the interest of large 
pharmaceutical companies into resuming the search 
for new and more effective drugs against antimicrobial 
resistant bacteria.58 This endeavour could also be 
strengthened with synergistic studies that show the 
mechanism(s) of combinatorial therapies.59 Researchers 
are also encouraged to investigate natural-based and 
semi-synthetic compounds as viable alternatives. Some 
medicinal scientists have identified chalcones,60 which 
are plant-based intermediates of flavonoids, and their 
ferrocenyl derivatives as potential drugs since these 
exhibit potent antimicrobial activity.61–64
Conclusion
Infection control practices and appropriate prescribing 
of antibiotics are essential tools against AMR. With the 
overuse of antibiotics on farms and in human medicine 
across the UK, it is evident that AMR continues to 
spread. However, this increase in the prevalence of 
antimicrobial resistant bacteria and their resulting 
infections could be slowed with the implementation of 
effective policies for antibiotic use in animals and farms, 
strict decontamination and sterilisation techniques and 
better regulations that encourage the search for new 
and novel drugs.
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